MIRM — Mirum Pharmaceuticals, Inc. stock price, charts and financials
QT55Mirum Pharmaceuticals, Inc.Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
104.33
-0.26-0.25%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -13.62 | Insider Own | 43.07% | Shs Outstand | 60.98M | Perf Week | -7.04% |
| Market Cap | 6.36B | Forward P/E | - | EPS next Y | -0.66 | Insider Trans | -0.59% | Shs Float | 52.46M | Perf Month | -14.42% |
| Enterprise Value | 6.30B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 13.86% | Perf Quarter | -1.38% |
| Income | -799.00M | P/S | 11.16 | EPS this Y | -14.79% | Inst Trans | - | Short Ratio | 7.37 | Perf Half Y | 0.51% |
| Sales | 570.00M | P/B | 26.29 | EPS next Y | 95.81% | ROA | -89.67% | Short Interest | 7.27M | Perf YTD | 32.08% |
| Book/sh | 3.97 | P/C | 16.48 | EPS next 5Y | - | ROE | -289.33% | 52W High | 130.01 -19.75% | Perf Year | 100.56% |
| Cash/sh | 6.33 | P/FCF | - | EPS past 3/5Y | - | ROIC | -11.30% | 52W Low | 50.25 107.62% | Perf 3Y | 304.54% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 89.14% - | Gross Margin | 81.36% | Volatility | 4.97% 4.32% | Perf 5Y | 639.93% |
| Dividend TTM | - | EV/Sales | 11.05 | EPS Y/Y TTM | -636.22% | Oper. Margin | -12.31% | ATR (14) | 5.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.99 | Sales Y/Y TTM | 69.14% | Profit Margin | -140.24% | RSI (14) | 37.74 | Recom | 1.94 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.09 | EPS Q/Q | -4376.67% | SMA20 | -9.77% | Beta | 0.50 | Target Price | 146.00 |
| Payout | 0.00% | Debt/Eq | 1.01 | Sales Q/Q | 42.86% | SMA50 | -4.80% | Rel Volume | 0.59 | Prev Close | 104.59 |
| Employees | 418 | LT Debt/Eq | 1.01 | Earnings | Aug 05 | SMA200 | 12.42% | Avg Volume | 964.57K | Price | 104.33 |
| IPO Date | Jul 18, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -3576.73% 7.89% | Net Debt/EBITDA | 0.00 | Volume | 569,430 | Change | -0.25% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $142 → $148 |
| Jun-15-26 | Reiterated | CLSA | $146 | |
| Jun-11-26 | Reiterated | Morgan Stanley | Overweight | $140 → $150 |
| May-19-26 | Initiated | Wolfe Research | Outperform | $145 |
| May-07-26 | Reiterated | Raymond James | Strong Buy | $164 → $165 |
| May-07-26 | Reiterated | H.C. Wainwright | Buy | $175 → $185 |
| May-07-26 | Reiterated | Stifel Nicolaus | $130 → $136 | |
| May-07-26 | Reiterated | Robert W. Baird | $112 → $129 | |
| May-07-26 | Reiterated | Evercore ISI Group | Outperform | $126 → $138 |
| May-07-26 | Reiterated | RBC Capital | Outperform | $128 → $142 |
Latest News
Jul-29-26
Jul-29-2604:01PM
Jul-16-26
Jul-13-26
Jul-13-2604:01PM
Jul-08-26
Jul-07-26
Jul-04-26
Jul-04-2603:48AM
Jun-29-26
Jun-29-2611:56AM
Jun-15-26
Jun-15-2610:06AM
Jun-11-26
Jun-11-2608:24AM
Company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 570 | 521 | 337 | 186 | 77 | 19 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 106 | 101 | 82 | 47 | 12 | 2 | 1 | 0 | 0 | |
| Gross Profit | 463 | 421 | 255 | 139 | 65 | 17 | -1 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 295 | 257 | 202 | 146 | 89 | 59 | 23 | 12 | 1 | |
| Research and Development | 238 | 186 | 141 | 103 | 107 | 131 | 82 | 43 | 2 | |
| Other Operating Expense | 0 | 0 | 0 | -1 | 0 | 1 | -1 | 0 | 0 | |
| Operating Income | -70 | -22 | -88 | -109 | -131 | -173 | -104 | -55 | -3 | |
| Interest Expense | 16 | 14 | 14 | 15 | 16 | 18 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -713 | 15 | 15 | -38 | 5 | 107 | 1 | 2 | -14 | |
| Net Income Before Taxes | -797 | -21 | -87 | -162 | -142 | -84 | -103 | -53 | -17 | |
| Income Taxes | 1 | 2 | 1 | 1 | -6 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -799 | -23 | -88 | -163 | -136 | -84 | -103 | -53 | -17 | |
| Net Income From Continuing Operations | -799 | -23 | -88 | -163 | -136 | -84 | -103 | -53 | -17 | |
| Net Income | -799 | -23 | -88 | -163 | -136 | -84 | -103 | -53 | -17 | |
| EPS (Recurring) | -13.61 | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 | |
| EPS (Basic, Before Extraordinaries) | -13.61 | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 | |
| EPS (Diluted) | -13.62 | -0.47 | -1.85 | -4.00 | -4.02 | -2.77 | -4.09 | -2.29 | -0.75 | |
| EBITDA | -761 | 17 | -49 | -136 | -123 | -65 | -102 | -52 | -17 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 10.80 | 7.58 | 5.89 | 6.51 | 8.61 | 25.18 | — | — | — | |
| Gross Margin | 81.23 | 80.81 | 75.67 | 74.73 | 84.42 | 89.47 | — | — | — | |
| Operating Margin | -12.28 | -4.22 | -26.11 | -58.60 | -170.13 | -910.53 | — | — | — | |
| Net Margin | -140.18 | -4.41 | -26.11 | -87.63 | -176.62 | -442.11 | — | — | — | |
| Shares Outstanding | 59 | 50 | 48 | 41 | 34 | 30 | 25 | 23 | 23 | |
| Market Capitalization | 6,155 | 3,949 | 1,985 | 1,210 | 663 | 479 | 437 | 564 | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Jul 06 '26 | Sale | 122.25 | 5,000 | 611,274 | 42,181 | Jul 08 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Jul 06 '26 | Sale | 122.27 | 20,000 | 2,445,383 | 194,309 | Jul 08 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Jul 06 '26 | Option Exercise | 2.94 | 20,000 | 58,720 | 214,309 | Jul 08 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | Jul 01 '26 | Sale | 120.00 | 2,721 | 326,520 | 3,114 | Jul 02 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | Jun 17 '26 | Sale | 101.95 | 2,594 | 264,458 | 5,835 | Jun 18 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Jun 09 '26 | Option Exercise | 26.49 | 2,393 | 63,391 | 47,181 | Jun 09 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Jun 08 '26 | Sale | 93.82 | 5,000 | 469,077 | 44,788 | Jun 09 |
| Radovich Peter | PRESIDENT AND COO | Jun 05 '26 | Option Exercise | 19.19 | 16,988 | 326,000 | 57,260 | Jun 08 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Jun 01 '26 | Sale | 95.84 | 30,000 | 2,875,103 | 194,309 | Jun 02 |
| Ramasastry Saira | Director | Jun 01 '26 | Sale | 100.00 | 3,977 | 397,700 | 0 | Jun 02 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Jun 01 '26 | Option Exercise | 2.94 | 30,000 | 88,080 | 224,309 | Jun 02 |
| Fischer Laurent | Director | May 29 '26 | Option Exercise | 0.00 | 3,977 | 0 | 10,727 | Jun 02 |
| Walbert Timothy P | Director | May 29 '26 | Option Exercise | 0.00 | 3,977 | 0 | 9,680 | Jun 02 |
| Cardon Lon | Director | May 29 '26 | Option Exercise | 0.00 | 3,977 | 0 | 9,680 | Jun 02 |
| Ramasastry Saira | Director | May 29 '26 | Option Exercise | 0.00 | 3,977 | 0 | 3,977 | Jun 02 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.